SCHEMBL29918604

SCHEMBL29918604

O=C(C1CCOC1)N(Cc1ccccc1)Cc1ccccc1

nearest known ligand 0.60

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.60
KMT2A Q03164 4/20 0.60
GAA P10253 4/20 0.44
KDM4E B2RXH2 4/20 0.44
LMNA P02545 4/20 0.44
CHRM5 P08912 2/20 0.44
ALDH1A1 P00352 4/20 0.44
NPSR1 Q6W5P4 2/20 0.44
ALOX12 P18054 1/20 0.44
HTT P42858 1/20 0.44
LPAR1 Q92633 2/20 0.44
LPAR5 Q9H1C0 2/20 0.44
HPGD P15428 1/20 0.41
RIPK1 Q13546 1/20 0.41
POLB P06746 2/20 0.41
SMN1; SMN2 Q16637 3/20 0.40
HSD17B10 Q99714 2/20 0.40
RAB9A P51151 1/20 0.40
MAPT P10636 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6061686 0.82 MEN1 (0.86) MEN1KMT2AGAAKDM4ELMNA
SCHEMBL29764514 0.82 MEN1 (0.86) MEN1KMT2AGAAKDM4ELMNA
SCHEMBL9260459 0.79 MEN1 (0.69) MEN1KMT2AGAAKDM4ELMNA
SCHEMBL9260456 0.79 MEN1 (0.69) MEN1KMT2AGAAKDM4ELMNA
SCHEMBL17474242 0.78 MEN1 (0.48) MEN1KMT2AGAAKDM4ELMNA
SCHEMBL17474238 0.78 MEN1 (0.48) MEN1KMT2AGAAKDM4ELMNA
SCHEMBL17474240 0.78 MEN1 (0.48) MEN1KMT2AGAAKDM4ELMNA
SCHEMBL6061687 0.78 MEN1 (0.78) MEN1KMT2AGAAKDM4ELMNA
SCHEMBL28694741 0.78 MEN1 (0.73) MEN1KMT2AGAAKDM4ELMNA
SCHEMBL1515889 0.76 RIPK1 (0.47) LMNAALDH1A1HPGDRIPK1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220324862-A1 PYRIDOPYRIMIDINONE COMPOUNDS ACERAND THERAPEUTICS (USA) LIMITED 2022-10-13 US disclosed
WO-2022212531-A1 PYRIDOPYRIMIDINONE COMPOUNDS ACERAND THERAPEUTICS (USA) LIMITED (US) 2022-10-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220324862-A1 PYRIDOPYRIMIDINONE COMPOUNDS RSU1, SOST, CCNA1 MEN1 414/4885KMT2A 3170/4885GAA 3706/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.